Data presented at ESMO Congress 2026 show lifileucel met its feasibility end point in refractory sarcoma, with 80% disease ...

UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.

Curran urges clinicians to treat ALL treatment guidance as a baseline and, when resources are limited, to focus on what ...

Fewer than two-thirds of patients prescribed augmentation begin infusions, and half of starters miss doses. Structured ...

Two pivotal trials, built on different designs and chemotherapy backbones, delivered comparable, if modest, survival gains in ...

Stanford's Richard Lafayette discusses 36-week povetacicept data in IgA nephropathy, including proteinuria, hematuria, and safety findings. Povetacicept, a dual inhibitor of B-cell activating factor ...

Most Medicaid enrollees who lost coverage during the unwinding were removed for procedural reasons, and expansion adults will ...

Anti-CGRP antibody exposure near conception was linked to higher spontaneous abortion risk in migraine, while propranolol was not, a cohort study found. Exposure to anticalcitonin gene-related peptide ...

Combined MRI and ultrasound raised sensitivity for bowel and uterosacral ligament endometriosis but reduced specificity in a prospective cohort study. Investigators at Stockholm South General Hospital ...

Dr. Haumschild compares SGLT2 inhibitors and GLP-1 receptor agonists as evidence in both classes keeps evolving. He acknowledges GLP-1s carry real budget impact that payers cannot ...

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...

The influx of novel therapies is expanding treatment options for patients with cancer, but distance, infrastructure, and ...